key: cord-0954197-mt4f2bjk
authors: Knight, S. C.; McCurdy, S. R.; Rhead, B.; Coignet, M. V.; Park, D. S.; Roberts, G. H. L.; Berkowitz, N. D.; Zhang, M.; Turissini, D.; Delgado, K.; Pavlovic, M.; Science Team, A.; Haug Baltzell, A. K.; Guturu, H.; Rand, K. A.; Girshick, A. R.; Hong, E. L.; Ball, C. A.
title: COVID-19 Susceptibility and Severity Risks in a Survey of Over 500,000 People
date: 2020-10-12
journal: nan
DOI: 10.1101/2020.10.08.20209593
sha: 3057cc342ba7d6b6d6698b5716f0799fb36c22de
doc_id: 954197
cord_uid: mt4f2bjk

The growing toll of the COVID-19 pandemic has heightened the urgency of identifying individuals most at risk of infection and severe outcomes, underscoring the need to assess susceptibility and severity patterns in large datasets. The AncestryDNA COVID-19 Study collected self-reported survey data on symptoms, outcomes, risk factors, and exposures for over 563,000 adult individuals in the U.S., including over 4,700 COVID-19 cases as measured by a self-reported positive nasal swab test. We observed significant associations between several risk factors and COVID-19 susceptibility and severity outcomes. Many of the susceptibility associations were accounted for by differences in known exposures; a notable exception was elevated susceptibility odds for males after adjusting for known exposures and age. We also leveraged the dataset to build risk models to robustly predict individualized COVID-19 susceptibility (area under the curve [AUC]=0.84) and severity outcomes including hospitalization and life-threatening critical illness amongst COVID-19 cases (AUC=0.87 and 0.90, respectively). The results highlight the value of self-reported epidemiological data at scale to provide public health insights into the evolving COVID-19 pandemic.

The COVID-19 pandemic has resulted in nearly 35 million COVID-19 cases and more than 29 1,000,000 deaths worldwide, 2 including nearly 7.5 million cases and more than 210,000 deaths in 30 the United States as of early October 2020. 3 The growing impact of the pandemic intensifies the 31 need for enhanced understanding of COVID-19 susceptibility and severity risk factors, not only 32 for public health experts, but also for individuals seeking to assess their own personalized risk. 33

Prior research has hypothesized that differences in COVID-19 susceptibility are related to age, 4 34 sex-dependent immune responses, 5 and genetics, 6,7 while heightened severity of COVID-19 35 illness is associated with risk factors such as age, 1, 4, 8, 9 sex, 5,10-12 underlying health 36 conditions, 1, 9, 10, 13, 14 and genetic factors including the ABO blood group. 15 Self-reported survey 37 data, which can easily be collected in the home, afford the opportunity to dynamically monitor 38 the continually evolving pandemic and allow for real-time estimation of individual-level 39 COVID-19 risk. [16] [17] [18] [19] Furthermore, self-reported surveys allow for collection of information about 40 known exposures, of which few epidemiological COVID-19 studies have explicitly accounted 41 for in association analyses to date. 20 42 43

In this paper, we aim to provide insight into factors associated with susceptibility and severity of 44 COVID-19 using a large survey cohort of 563,141 AncestryDNA customers who have consented 45 to participate in the AncestryDNA COVID-19 Study (Supplementary Tables 1-6 ). 6 We found 46 that known exposure differences account for many associations for a positive COVID-19 test 47 result. 18,21 Further analysis yielded evidence that males may be more susceptible to COVID-19 48 than females after adjusting for known exposures and age. While several previous reports have 49 documented increased severity risk in males, 5,11,13 the finding of sex-based differences in 50 Differential symptomology. Among symptomatic people who were reported a COVID-19 test 143 result, those reporting moderate to severe change in taste or smell (OR=7.26; 95% CI=(5.54, 144 9.50)), fever (OR=1.60; 95% CI=(1.28, 2.01)), or feeling tired or fatigue (OR=1.41; 95% 145 CI=(1.05, 1.89)) were more likely to test positive (Figure 3, Supplementary Table 7) . Those 146 reporting moderate to severe runny nose (OR=0.59; 95% CI=(0.47, 0.75)) or sore throat 147 (OR=0.49; 95% CI=(0.39, 0.62)) were more likely to test negative, consistent with previous 148 reports that these symptoms are more indicative of influenza or the common cold (Figure 3 , 149 Supplementary Table 7) . 17 CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 12, 2020. . https://doi.org/10.1101/2020.10.08.20209593 doi: medRxiv preprint Predictive risk models. We developed models that predict an individual's COVID-19 risk 157 (positive test result or severity). Many predictive models for COVID-19 infection and severity 158 outcomes have been reported in the literature. 1, [16] [17] [18] 24, 31 To date, few large-scale studies have 159 investigated both susceptibility and severity risk within the same dataset, offering a consistent 160 and comprehensive understanding of similarities and differences between the two outcomes. 161

For each of the risk models we developed, the survey data were divided into independent training 162 and test cohorts, and additional association analyses were performed on the training data to guide 163 the selection of risk factors for the models (Methods, Supplementary Tables 17-20). In contrast 164 to association analyses, these risk models are based on penalized logistic regression with cross-165 validation in order to allow for transferability to independent cohorts. 166

The susceptibility models were designed to predict a COVID-19 result (positive or negative) 167 from risk factors among testers. In addition to our own two models, we also replicated two self-168 reported models from the literature in order to assess how well our models perform relative to a 169 respected benchmark. 18 In all, we compared four models: our model based on demographics and 170 exposures (referred to throughout as "Dem + Exp"); our model based on demographics, 171 exposures, and symptoms (referred to throughout as "Dem + Exp + Symp"); and the two 172 literature-based models designed with nearly identical risk factors as reported previously in 173 another large, self-reported study ("How We Feel" (HWF); models referred to as "HWF Exp + 174 CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 12, 2020. . https://doi.org/10.1101/2020.10.08.20209593 doi: medRxiv preprint included one or more symptoms outperformed the model without symptoms (Dem + Exp), 179 underscoring the value of self-reported symptoms for discriminating between cases and controls. Table 25) . 188 189 We also trained severity models to predict hospitalization and critical illness progression among 190 COVID-19 cases. We included a number of risk factors and symptoms most associated with 191 severe COVID-19 outcomes from the literature and/or our training dataset (Figure 3, 192 Supplementary Tables 18 and 19); these included age, 1, 8, 9, 13 sex, 1,5,11-13 morbid obesity (BMI >= 193 40), 1, 32 and health conditions, 1, 9, [12] [13] [14] as well as shortness of breath, 23 fever, feeling tired or 194 fatigue, dry cough, and diarrhea for symptoms. Both models performed robustly on an 195 independent holdout dataset ( Figure 4 ). The hospitalization model had an AUC of 0.87 +/-0. 03, 196 and the critical case model had an AUC of 0.90 +/-0.03. For both severity models, shortness of 197 breath was the most predictive risk factor. We were concerned that this might seem obvious, so 198 we designed models excluding this symptom which also achieved moderately high 199 discriminative performance (AUC > 0.80; Supplementary Figure 4 ). The severity models 200 performed comparably when stratifying by age, sex, and genetic ancestry (Supplementary Tables  201   . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 12, 2020. . https://doi.org/10.1101/2020.10.08.20209593 doi: medRxiv preprint 26-27), and there was no significant overfitting bias as evidenced by comparable train-test 202 performances (Supplementary Table 25) . 203

In contrast with susceptibility models, we did not evaluate the severity models against literature-205 based models, as the vast majority of these models include clinical factors (e.g., bloodwork) not 206 measured in this self-reported dataset. 1, 16, 31 However, the models presented here perform on par 207 with many previously reported models despite the absence of clinical factors, suggesting the 208 potential value of self-reported data to identify the most at-risk COVID-19 individuals. 16 susceptibility and severity outcomes. The self-report framework provides fast, low-cost, 213 population-scale data that are particularly valuable in a pandemic, where knowledge is both 214 limited and evolving rapidly based on changing circumstances. Additionally, the broad collection 215 mechanism enables data-gathering from many more and potentially more diverse participants 216 than typically seen in a medical setting, and participants can safely provide data from their 217 homes. Moreover, self-reported data have been shown to be useful for estimating population 218 prevalence, 19 and models built from these data may help to contextualize individual risk prior to 219 infection with COVID-19. 1, [16] [17] [18] 24 ,31 220 221

The study highlights exposure burden as the primary risk factor for COVID-19 susceptibility, 222 and the importance of accounting for known exposures when assessing differences in 223 susceptibility to COVID-19. Few studies have measured and explicitly adjusted for known 224 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted October 12, 2020. . https://doi.org/10.1101/2020.10.08.20209593 doi: medRxiv preprint COVID-19 exposures at this scale. 20 We found elevated exposure levels for younger individuals, 225 as well as individuals of admixed African-European or admixed Amerindian ancestry, which 226 account for at least some of the elevated susceptibility risk for these individuals as evidenced by 227 attenuation of ORs after adjustment for known exposures and age. This finding is consistent with 228 previous reports about elevated exposure levels for younger and minority groups within the 229 U.S. 26-30 By contrast, we found reduced exposure levels among those reporting one or more pre-230 existing health conditions. The lower exposure burden observed for these individuals may reflect 231 pre-pandemic differences in public interactions or increased precautions to mitigate exposure, 232

given published severity risks associated with these conditions. 1,9,13,14,33,34 233 234 Importantly, we found elevated susceptibility risk in males after adjusting for age and known 235 exposures, and the adjusted odds were not attenuated compared to the unadjusted odds. This 236 finding is distinct from previous findings on elevated severity risk in males. 1, 5, 11 This result could 237 be due to differences between men and women in behaviors, unknown exposures, biology, 238 genetics, 5-7 or other risk factors not measured within this dataset. 239

Another major contribution of this study is the development of novel risk models for predicting 241 an individual's COVID-19 susceptibility and severity risk. The risk models presented here 242 perform comparably or better than similar and more complex models reported previously. 16-243 18,24,31 This study is also one of few to date to assess and demonstrate relatively strong 244 performance of risk models across different age, sex, and genetic ancestry groups, 17 highlighting 245 the potential utility and generalizability of these models to broader populations. Such models 246 may be useful to clinicians to estimate an individual's risk of infection and/or severity risk, or as 247 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted October 12, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted October 12, 2020. . https://doi.org/10.1101/2020.10.08.20209593 doi: medRxiv preprint Methods 260 Ethics statement. Ethics statement. All data for this research project were from subjects who 261 have provided informed consent to participate in AncestryDNA's Human Diversity Project, as 262 reviewed and approved by our external institutional review board, Advarra (formerly Quorum). 263

All data were de-identified prior to use. 264 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted October 12, 2020. . https://doi.org/10.1101/2020.10.08.20209593 doi: medRxiv preprint Study population. Collection of self-reported COVID-19 outcomes from AncestryDNA 265 customers who consented to research, participation criteria for the study, and the survey design 266 are described in a genome-wide association study (GWAS) on a very similar AncestryDNA 267 dataset, which identified three novel, genome-wide significant loci. 6 Here, participants reporting 268 a negative test result were also assessed for symptoms and clinical outcomes. Analyses presented 269 here were performed with data collected between 22 April and 6 July 2020. 270

Outcome definitions. The study assessed three outcomes: one for susceptibility and two for 271 severity of COVID-19 infection. Cases for COVID-19 susceptibility were individuals who 272 responded, "Yes, and was positive" to the question, "Have you been swab tested for COVID-19, 273 commonly referred to as coronavirus?" Responders who answered, "Yes, and was negative" 274 were used as controls for the susceptibility analysis. 275

The hospitalization outcome was defined among COVID-19-positive cases if a participant 276 responded "Yes" to a binary question about experiencing symptoms due to COVID-19 illness 277 and "Yes" to the hospitalization question ("Were you hospitalized due to these symptoms?). 278 Controls were defined by a response of "No" to the hospitalization question in addition to 279 reporting a self-reported positive COVID-19 test result. 6 280 281 Critical cases of COVID-19 were defined via a response of "Yes" to one or more questions about 282 ICU admittance ("Were you hospitalized in the Intensive Care Unit [ICU] with a ventilator?" or 283 "Were you hospitalized in the Intensive Care Unit [ICU] with oxygen?") or, alternatively, self-284 reported septic shock, organ failure, or respiratory failure resulting from a COVID-19 infection 285 ("Have you had any of the following complications due to your illness? Select all that apply."). 13 286 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted October 12, 2020. . https://doi.org/10.1101/2020.10.08.20209593 doi: medRxiv preprint Controls were defined by a response of "No" across all of these questions in addition to self-287 reporting a positive COVID-19 test result. 288 289 Genetic sex and ancestry definitions. All individuals were genotyped, using previously 290 described general genotyping and quality control procedures. 35 Both sex and genetic ancestry 291

were defined for individuals based on their genotypes. Genetic ancestry was estimated using a 292

proprietary algorithm to estimate continental admixture proportions. 36 Briefly, this algorithm 293 uses a hidden Markov model to estimate unphased diploid ancestry across the genome by 294 comparing haplotype structure to a reference panel. 295

Data preparation for analysis. Multiple-choice categorical questions were one-hot ("dummy") 297 encoded as binary risk factors with k-1 degrees of freedom, where k corresponds to the number 298 of fields for a given question. In this framework, a value of 0 across all k-1 fields corresponds to 299 a response of "None" or "None of the above" for a given question. 300

We considered several risk factors and outcomes questions in our association analyses and risk 302 modeling efforts, some of which are summarized in Supplementary Tables 1 and 2. Based on the 303 dependency structure within our survey, not every question was surfaced to every participant 304 included within our study. As such, we made the following inferences: 305 • Participants reporting "No" to a binary question about symptoms arising from COVID-19 306 infection ("Did you experience symptoms as a result of your condition?") were 307 designated as negatives for dependent questions about individual symptoms ("Between 308 the beginning of February 2020 and now, have you had any of the following 309 symptoms?"), hospitalization due to symptoms ("Were you hospitalized due to these 310 symptoms?"), ICU admittance due to symptoms ("Were you hospitalized in the Intensive 311

Care Unit [ICU] with a ventilator?" or "Were you hospitalized in the Intensive Care Unit 312 ([ICU] with oxygen?"), and medications prescribed due to symptoms ("Did a doctor treat 313 you with medication for your illness?") 314 • Participants reporting "No" to a binary question about hospitalization ("Were you 315 hospitalized due to these symptoms?") were assigned to a hospital duration of 0 days and 316 designated as negative for ICU admittance due to symptoms. 317 • Participants reporting "No" to a binary question about medications prescribed due to 318 symptoms ("Did a doctor treat you with medication for your illness?") were designated as 319 negative for individual medication fields from a dependent question ("What medication 320 were you treated with?"). 321

Responses to a question about individual symptoms ("Between the beginning of February 2020 323 and now, have you had any of the following symptoms?") were converted to a binary variable 324 based on the following mapping: 0 = None, Very Mild, Mild; 1 = Moderate, Severe, Very 325

Severe. 326 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted October 12, 2020. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted October 12, 2020. . https://doi.org/10.1101/2020.10.08.20209593 doi: medRxiv preprint

Data splitting. All data were used in the OR analyses; data splitting was performed for risk 343 modeling only. Prior to model training, the data were split with a fixed random seed. For 344 susceptibility models without symptoms, 75% of the data were used for model training and 25% 345 of the data were used for holdout evaluation. For severity models and susceptibility models with 346 symptoms, 50% of the data were used for model training and 50% of the data were used for 347 holdout evaluation. The larger holdout set allows for more robust stratified analyses of model 348 performances, given the smaller overall cohort sizes for models with symptoms. 349 350

Predictive risk models. Logistic regression models were trained and evaluated using the scikit-351 learn package in Python. Here, we used lasso-penalized multiple logistic regression with cross-352 validation on the training dataset in order to select an optimal hyperparameterization for 353 generalizability to independent test sets. 37 The penalized objective function for regression was 354 weighted by inverse prevalence to address class imbalance and was framed as follows: 355 CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted October 12, 2020. . https://doi.org/10.1101/2020.10.08.20209593 doi: medRxiv preprint coefficients, n is the total number of risk factors in the model, β i is the regression coefficient for 365 the ith risk factor in the model, and Ln is the natural logarithm. 366

Risk factor selection and model training. We chose risk factors based on a minimal subset of 367 nominally significant ORs within our training data as well as literature guidance. 1, 4, 5, 9, [11] [12] [13] [14] For 368 the susceptibility models without symptoms, we included a subset of exposure-related questions, 369 based on the training OR analyses, as well as two demographic variables (age and sex). For 370 susceptibility models with symptoms, we additionally included the five symptoms most 371 differentiated between symptomatic negative and positive testers from our training ORs. For the 372 severity models, we included pre-existing conditions, based on the training OR analyses, 373 predictive symptoms within our training dataset 36 , morbid obesity (BMI >= 40), age, and sex. 374

The full list of risk factors for each model is included in Supplementary Table 20 . 375 376 Once final risk factors were selected, we performed 5-fold cross-validation with grid search on 377 our training dataset to select an optimal lasso regularization parameter lambda. 37 For the grid 378 search, we scanned 8 different values for lambda, equally partitioned geometrically across a 4-379 log space. We then re-trained on the entire training dataset with the optimal lambda, and 380 evaluated the final model on the holdout dataset. 381 382 Model thresholding. Phenotypes were predicted from the output of trained models based on a 383 50% probability threshold (i.e., logistic model output > 0.5). Sensitivity and specificity were then 384 calculated based on the true vs. predicted binary outcomes. 385 386 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted October 12, 2020. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted October 12, 2020. . https://doi.org/10.1101/2020.10.08.20209593 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted October 12, 2020. . https://doi.org/10.1101/2020.10.08.20209593 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted October 12, 2020. . https://doi.org/10.1101/2020.10.08.20209593 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted October 12, 2020. . https://doi.org/10.1101/2020.10.08.20209593 doi: medRxiv preprint CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 12, 2020. . https://doi.org/10.1101/2020.10.08.20209593 doi: medRxiv preprint CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 12, 2020. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 12, 2020. . https://doi.org/10.1101/2020.10.08.20209593 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 12, 2020. . https://doi.org/10.1101/2020.10.08.20209593 doi: medRxiv preprint ROC curves for severity models to predict either hospitalization (red) or critical illness 445 progression (black) among COVID-19 cases. g) Classification confusion matrix for the 446 hospitalization risk model. h) Classification confusion matrix for the critical case risk model. 447

Refer to Methods as well as Supplementary Tables 20-27 for additional model performance data  448 and model risk factor information. 449 450 451 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 12, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 12, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 12, 2020. with COVID-19 in our ORs in the training dataset, as well as reports about these variables as 500 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 12, 2020. AncestryDNA-trained AUC=0.90 and HWF-trained AUC=0.87; Figure 4 ). 18 This result could be 510 due to differences in survey flow design, demographics, or the relative prevalences of self-511 reported symptoms between the two datasets. We re-trained and evaluated our models on a 512 subset of symptomatic COVID-19 testers (positives and negatives) reporting at least one 513 symptom of moderate or greater intensity. The performances of all models that included 514 symptoms were slightly attenuated in this cohort, with AUCs for the HWF models approaching 515 previous reports (HWF Symp: AncestryDNA-trained AUC=0.80 and HWF Exp + Symp: 516

AncestryDNA-trained AUC=0.87); the model without symptoms performed the same 517 (Supplementary Figure 3) . This suggests that predicting COVID-19 cases on the basis of 518 symptoms alone is more challenging when symptoms are less differentiated between positive and 519 negative testers. 520 521 522 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 12, 2020. The survey flow was as described previously, 6 with the addition of symptom and clincial 528 assessment for negative testers. 529 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 12, 2020. The survey flow was as described previously, 6 with the addition of symptom and clincial 534 assessment for negative testers. 535 536 537 538 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 12, 2020. 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 12, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 12, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 12, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 12, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 12, 2020. reporting a test result (positive or negative) based on the self-reported response to the following 557 question: "Have you been swab tested for COVID-19, commonly referred to as coronavirus?" 558

The following groups served as reference populations for the odds ratio calculations: European 559 genetic ancestry (Genetic Ancestry), Ages 50-64 (Age), Female (Genetic Sex), and Not Obese 560 (BMI < 30, Obesity). Note that symptoms odds ratios were calculated in a binary fashion among 561 symptomatic customers only (Methods). 562 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 12, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 12, 2020. reporting a test result (positive or negative) based on the self-reported response to the following 568 question: "Have you been swab tested for COVID-19, commonly referred to as coronavirus?" 569

The following groups served as reference populations for the odds ratio calculations: European 570 genetic ancestry (Genetic Ancestry), Ages 50-64 (Age), Female (Genetic Sex), and Not Obese 571 (BMI < 30, Obesity). Note that symptoms odds ratios were calculated in a binary fashion among 572 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 12, 2020. . https://doi.org/10.1101/2020.10.08.20209593 doi: medRxiv preprint symptomatic customers only (Methods). Here, odds ratios were adjusted for four known 573 exposures (Y/N if any). 574 575 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 12, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 12, 2020. reporting a test result (positive or negative) based on the self-reported response to the following 581 question: "Have you been swab tested for COVID-19, commonly referred to as coronavirus?" 582

The following groups served as reference populations for the odds ratio calculations: European 583 genetic ancestry (Genetic Ancestry), Ages 50-64 (Age), Female (Genetic Sex), and Not Obese 584 (BMI < 30, Obesity). Note that symptoms odds ratios were calculated in a binary fashion among 585 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 12, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 12, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 12, 2020. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 12, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 12, 2020. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 12, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 12, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 12, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 12, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 12, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 12, 2020. . https://doi.org/10.1101/2020.10.08.20209593 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 12, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 12, 2020. Obesity). Note that symptoms odds ratios were calculated in a binary fashion among 687 symptomatic customers only (Methods). 688 689 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 12, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 12, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 12, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 12, 2020. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 12, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 12, 2020. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 12, 2020. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 12, 2020. 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted October 12, 2020. . https://doi.org/10.1101/2020.10.08.20209593 doi: medRxiv preprint Risk factors for models were selected based on literature as well as nominally significant odds 735 ratios within the training dataset (Methods). 95% confidence intervals for the area under the 736 curve (AUC) on the holdout dataset were estimated via bootstrapping (Methods). 737 738 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted October 12, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted October 12, 2020. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted October 12, 2020. . https://doi.org/10.1101/2020.10.08.20209593 doi: medRxiv preprint 839 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted October 12, 2020. . https://doi.org/10.1101/2020.10.08.20209593 doi: medRxiv preprint 840 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted October 12, 2020. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted October 12, 2020. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted October 12, 2020. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted October 12, 2020. . https://doi.org/10.1101/2020.10.08.20209593 doi: medRxiv preprint

Case/control status is defined based on self-reported COVID-19 positive test result. The Dem + 755

Metric performance columns reflect mean and nominal 95% 757 confidence intervals for each metric on an internal

Cohort-level receiver operator characteristic (ROC) curves were constructed from predicted class 759 probabilities of models trained on the entire training dataset (Methods)

The 785 literature-based HWF Symp model contains 7 symptoms most commonly associated with 786 COVID-19 (Supplementary Table 20). 18 Metric performance columns reflect mean and nominal 787 95% confidence intervals for each metric on an internal

Cohort-level receiver operator characteristic (ROC) curves were constructed from predicted class 789 probabilities of models trained on the entire training dataset (Methods)

References 864

Factors associated with COVID-19-related death using 865

World Health Organization. Coronavirus Disease (COVID-19)-Weekly Epidemiological 867

Centers for Disease Control and Prevention (CDC). Coronavirus disease 2019

CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-872 ncov%2Fcases-updates%2Fcases-in-us.html#cases

Age-dependent effects in the transmission and 874 control of COVID-19 epidemics

Sex differences in immune responses that underlie 876 COVID-19 disease outcomes

AncestryDNA COVID-19 Host Genetic Study Identifies 878

Single-cell RNA expression profiling of ACE2, the receptor of SARS-CoV-2

Global, regional, and national estimates of the population at increased risk of 886 severe COVID-19 due to underlying health conditions in 2020: a modelling study

Impact of 889 sex and gender on COVID-19 outcomes in Europe

Baseline Characteristics and Outcomes of 1591 Patients Infected With 891

SARS-CoV-2 Admitted to ICUs of the Lombardy Region

Presenting Characteristics, Comorbidities, and Outcomes Among 5700

Patients Hospitalized With COVID-19 in the New York City Area

Comorbidity and its impact on 1590 patients with COVID-19 in China: a 895 nationwide analysis

Genomewide Association Study of Severe Covid-19 with Respiratory 897

Prediction models for diagnosis and prognosis of covid-19: systematic 899 review and critical appraisal

Real-time tracking of self-reported symptoms to predict potential COVID-901 19

Population-scale longitudinal mapping of COVID-19 symptoms, 903 behaviour and testing

Validation of self-reported chronic 905 conditions and health services in a managed care population

Risk of COVID-19 among front-line health-care workers and the 908 general community: a prospective cohort study

Coronavirus Disease 2019 Case Surveillance -United States

Symptom Screening at Illness Onset of Health Care Personnel With SARS-912

CoV-2 Infection in King County

Dyspnea rather than fever is a risk factor 914 for predicting mortality in patients with COVID-19

Individualizing Risk Prediction for Positive Coronavirus Disease

Infectious diseases epidemiology

COVID-921 19 and Hidden Housing Vulnerabilities: Implications for Health Equity

Hospitalization and Mortality 924 among Black Patients and White Patients with Covid-19

Assessing differential impacts of COVID-19 on black communities

COVID-19 and Racial/Ethnic 929 Disparities

As virus surges, younger people account for 'disturbing' 931 number of cases

Development and validation of a model for individualized prediction of 933 hospitalization risk in 4,536 patients with COVID-19

Obesity and its Implications for COVID 19 Mortality

Coronavirus disease: people with 937 certain medical conditions

Coronavirus disease: scientific 942 evidence for conditions that increase risk of severe illness

Clustering of 770,000 genomes reveals post-colonial population structure of 946

Ethnicity Estimate 2019 White Paper

The Elements of Statistical Learning: Data Mining, Inference, and Prediction

Centers for Disease Control and Prevention (CDC). Symptoms of Coronavirus

Household secondary attack rate of COVID-19 and associated determinants 955 in Guangzhou, China: a retrospective cohort study

Clinical characteristics of 24 asymptomatic infections with COVID-19 screened 958 among close contacts in Nanjing